Alzamend Neuro, Inc.

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro (Nasdaq: ALZN) received a Compliance Notice dated September 14, 2026 confirming it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Rule, and the matter is now closed. The company evidenced stockholders' equity of $5,802,680 in its 10-Q for the quarter ended July 31, 2026, filed September 10, 2026, versus the $2.5 million minimum required. Alzamend had been notified on March 20, 2026 that it failed continued-listing standards; its remediation plan was accepted and it was granted until September 16, 2026 to regain compliance. CEO Stephan Jackman said the company's full focus returns to advancing AL001 through four Phase II clinical trials in partnership with Massachusetts General Hospital, with the bipolar disorder cohort initiated in April 2026 and Alzheimer's, MDD, and PTSD cohorts to follow.

•1mo ago

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Alzamend Neuro announced that an abstract detailing Phase 1/2A neuroimaging data for AL001 has been accepted for a poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience. The study found that AL001, a novel organic lithium salt, matches blood levels of standard lithium carbonate while demonstrating potential for enhanced delivery to targeted brain regions and reduced systemic exposure. These results address FDA regulatory requirements for a new drug formulation and support the development of a differentiated therapy with a potentially better safety profile for patients with bipolar disorder and other conditions.

•2mo ago

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

Alzamend Neuro announced that pharmacokinetic imaging data from its Phase 1/2A trial of AL001 has been accepted for an oral presentation at the ISMRM X-Nuclei MR workshop in Barcelona. The study results confirm that AL001 matches blood levels of standard lithium carbonate, addressing FDA regulatory requirements, while demonstrating potential for dose-sparing benefits and improved brain delivery. The company highlighted that the data provides a non-invasive look at how the novel lithium formulation behaves in brain tissue over time compared to traditional therapies.

•2mo ago

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Alzamend Neuro closed an initial $7.5 million tranche of a Series D Convertible Preferred Stock purchase agreement with Ault Lending, totaling a potential $25 million commitment. The deal provides for a second tranche of $2.5 million and $15 million in monthly installments over 15 months to fund clinical trials for AL001 and ALZN002. Proceeds will be used for working capital and corporate purposes, supporting the development of treatments for Alzheimer's and psychiatric disorders.

•2mo ago